Actavia Life Sciences Inc. (RASP)
OTCQB OTCQB Primary Summary
Actavia Life Sciences Inc. (RASP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Actavia Life Sciences Inc. ever had a stock split?
Actavia Life Sciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | Keeren Shah CEO | OTCQB Exchange | 753888106 CUSIP |
| US Country | 1 Employees | - Last Dividend | 20 Sep 2016 Last Split | - IPO Date |
Overview
Actavia Life Sciences, Inc. is a biotechnology firm focused on the development of therapeutics for the treatment of leukemia, with a specific emphasis on acute myeloid leukemia (AML) and other forms of leukemia and lymphoma. Initially named Rasna Therapeutics, Inc., the company underwent a name change in October 2023, strengthening its identity in the biotech industry. Founded in 2013 and based in New York, New York, Actavia Life Sciences, Inc. is at the forefront of AML research, aiming to provide innovative treatments that improve patient outcomes and quality of life. Harnessing its expertise in the field, Actavia is developing cutting-edge therapeutics designed to target and disrupt critical pathways associated with the progression of leukemia, ensuring a focused approach towards tackling this challenging group of cancers.
Products and Services
-
RASP-201
RASP-201 stands as a pioneering development from Actavia Life Sciences, Inc., representing a novel, orally dosed, selective reversible inhibitor geared towards targeting lysine specific demethylase. This pathway is crucial as it blocks differentiation and confers a poor prognosis in patients with acute myeloid leukemia. Through inhibiting this pathway, RASP-201 aims to counteract one of the fundamental mechanisms through which AML sustains itself, potentially offering a new avenue for treatment that could significantly alter the course of the disease.
-
RASP-301
Currently in the pre-clinical stage, RASP-301 represents Actavia's ambition to expand its portfolio of leukemia treatments. As a new chemical entity (NCE) for NPM1 mutations, RASP-301 is being developed to treat refractory AML with the intent of reducing toxicity. This focus on NPM1 mutations, prevalent in a portion of AML patients, could provide a targeted therapy option, offering hope for those who have not responded well to existing treatments. The development of RASP-301 underscores Actavia Life Sciences, Inc.'s commitment to leveraging scientific innovation to address unmet needs in the leukemia treatment landscape.
